Skip Navigation

JNCI Journal of the National Cancer Institute 2003 95(5):338-340; doi:10.1093/jnci/95.5.338
© 2003 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Jordan, V. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jordan, V. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 95, No. 5, 338-340, March 5, 2003
© 2003 Oxford University Press

EDITORIAL

Is Tamoxifen the Rosetta Stone for Breast Cancer?

V. Craig Jordan

Correspondence to: V. Craig Jordan, OBE, Ph.D., D.Sc., Northwestern University Medical School, Robert H. Lurie Comprehensive Cancer Center, 8258 Olson, 303 E. Chicago Ave., Chicago, IL 60611 (e-mail: vcjordan@northwestern.edu).

The first 150 words of the full text of this article appear below.

During the closing stages of the 18th century, a young French general named Napoleon Bonaparte led an expedition from France to Egypt. The goals were to: 1) establish a base for an advance over land to attack British interests in India, and 2) collect scientific information and artifacts from the ancient land of Egypt. Unfortunately, the military campaign turned into a strategic disaster when Admiral Nelson sank Napoleon‘s transport fleet in the Battle of the Nile. History was to record, however, that the Egyptian venture was not a complete failure; the scientific expedition uncovered an artifact that would become the conduit to relive the story of a lost civilization.

In the ruins surrounding the French soldiers were strange drawings known as hieroglyphs. No one had any idea what the designs meant until chance intervened. French troops who were tasked to strengthen the defenses of an abandoned fort near Rosetta uncovered . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
A. Merglen, H. M. Verkooijen, G. Fioretta, I. Neyroud-Caspar, V. Vinh-Hung, G. Vlastos, P. O. Chappuis, M. Castiglione, E. Rapiti, and C. Bouchardy
Hormonal therapy for oestrogen receptor-negative breast cancer is associated with higher disease-specific mortality
Ann. Onc., May 1, 2009; 20(5): 857 - 861.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. M. O'Regan, C. Osipo, E. Ariazi, E. S. Lee, K. Meeke, C. Morris, A. Bertucci, M. A.B. Sarker, R. Grigg, and V. C. Jordan
Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
Clin. Cancer Res., April 1, 2006; 12(7): 2255 - 2263.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
S. M Dougherty, W. Mazhawidza, A. R Bohn, K. A Robinson, K. A Mattingly, K. A Blankenship, M. O Huff, W. G McGregor, and C. M Klinge
Gender difference in the activity but not expression of estrogen receptors {alpha} and {beta} in human lung adenocarcinoma cells.
Endocr. Relat. Cancer, March 1, 2006; 13(1): 113 - 134.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. C. Murphy, Y. Niu, L. Snell, and P. Watson
Phospho-Serine-118 Estrogen Receptor-{alpha} Expression Is Associated with Better Disease Outcome in Women Treated with Tamoxifen
Clin. Cancer Res., September 1, 2004; 10(17): 5902 - 5906.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Goldhirsch, W. C. Wood, R. D. Gelber, A. S. Coates, B. Thurlimann, and H.-J. Senn
Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer
J. Clin. Oncol., September 1, 2003; 21(17): 3357 - 3365.
[Abstract] [Full Text] [PDF]